Skip to main content
. 2023 Jan 4;12:1083500. doi: 10.3389/fonc.2022.1083500

Figure 3.

Figure 3

Whole-body 18F-fluorodeoxyglucose (FDG)-positron emission tomography with computed tomography (PET-CT) before and after treatment. (A) FDG-PET-CT before treatment, showing abnormal FDG uptake in the facial skin, peri-atrial, pelvic (arrows), cervical, axillary, and inguinal lymph nodes, and colon. (B) Follow-up FDG-PET-CT after treatment, showing the disappearance of abnormal FDG uptake.